Skip to main content
Journal cover image

Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430.

Publication ,  Journal Article
Stinchcombe, TE; Mauer, AM; Hodgson, LD; Herndon, JE; Lynch, TJ; Green, MR; Vokes, EE; Cancer and Leukemia Group B,
Published in: J Thorac Oncol
November 2008

BACKGROUND: Cancer and Leukemia Group B trial 9430 was a randomized phase II trial which investigated the safety and activity of four novel doublets in untreated extensive stage small cell lung cancer. The results of the paclitaxel and cisplatin arm have not been reported. PATIENTS AND METHODS: Patients received paclitaxel 230 mg/m followed by cisplatin 75 mg/m on day 1 every 21 days. All patients received granulocyte colony stimulating factor 5 microg/kg/d beginning on day 3 of each cycle. RESULTS: The patient characteristics of the 34 patients assigned to this treatment arm were: median age 61.5 years (range 41-82), male (76%), performance status 0 (41%), 1 (32%), and 2 (26%). An objective response was observed in 23 patients (68%; 95% confidence interval (CI): 49-83%); 2 complete responses (6%) and 21 partial responses (62%). Median progression-free survival time was 5.6 months (95% CI: 4.8-7.1 month), and median overall survival time was 7.7 months (95% CI: 7.2-12.6 months). The 1-year survival rate observed was 29% (95% CI: 15-45%). Grade 3/4 neutropenia and thrombocytopenia was observed in 5 (15%) and 4 (12%) patients, respectively. Two patients developed febrile neutropenia including one patient who died of neutropenic sepsis. Grade 3/4 nonhematologic observed were: sensory neuropathy in eight patients (24%); and hyperglycemia, malaise and nausea were all observed in four patients (12%). CONCLUSIONS: Cancer and Leukemia Group B will not pursue further investigation of paclitaxel and cisplatin due to the modest activity and the toxicity observed on this trial.

Duke Scholars

Published In

J Thorac Oncol

DOI

EISSN

1556-1380

Publication Date

November 2008

Volume

3

Issue

11

Start / End Page

1301 / 1307

Location

United States

Related Subject Headings

  • Survival Rate
  • Prognosis
  • Paclitaxel
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Middle Aged
  • Maximum Tolerated Dose
  • Male
  • Lung Neoplasms
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Stinchcombe, T. E., Mauer, A. M., Hodgson, L. D., Herndon, J. E., Lynch, T. J., Green, M. R., … Cancer and Leukemia Group B, . (2008). Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430. J Thorac Oncol, 3(11), 1301–1307. https://doi.org/10.1097/JTO.0b013e318187494a
Stinchcombe, Thomas E., Ann M. Mauer, Lydia D. Hodgson, James E. Herndon, Thomas J. Lynch, Mark R. Green, Everett E. Vokes, and Everett E. Cancer and Leukemia Group B. “Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430.J Thorac Oncol 3, no. 11 (November 2008): 1301–7. https://doi.org/10.1097/JTO.0b013e318187494a.
Stinchcombe TE, Mauer AM, Hodgson LD, Herndon JE, Lynch TJ, Green MR, et al. Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430. J Thorac Oncol. 2008 Nov;3(11):1301–7.
Stinchcombe, Thomas E., et al. “Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430.J Thorac Oncol, vol. 3, no. 11, Nov. 2008, pp. 1301–07. Pubmed, doi:10.1097/JTO.0b013e318187494a.
Stinchcombe TE, Mauer AM, Hodgson LD, Herndon JE, Lynch TJ, Green MR, Vokes EE, Cancer and Leukemia Group B. Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430. J Thorac Oncol. 2008 Nov;3(11):1301–1307.
Journal cover image

Published In

J Thorac Oncol

DOI

EISSN

1556-1380

Publication Date

November 2008

Volume

3

Issue

11

Start / End Page

1301 / 1307

Location

United States

Related Subject Headings

  • Survival Rate
  • Prognosis
  • Paclitaxel
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Middle Aged
  • Maximum Tolerated Dose
  • Male
  • Lung Neoplasms
  • Humans